Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency

Annals of Neurology

Volumn 54, Issue SUPPL. 6, 2003, Pages

  Gropman, Andrea ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; 4 HYDROXYBUTYRIC ACID; 4 HYDROXYBUTYRIC ACID DEHYDROGENASE; 6,7,8,9 TETRAHYDRO 5H BENZOCYCLOHEPTEN 5 OL 4 YLIDENEACETIC ACID; ANTICONVULSIVE AGENT; CARBON 13; DEUTERIUM; EXCITATORY AMINO ACID; GLUTAMATE DECARBOXYLASE; GLUTAMATE DEHYDROGENASE; GLUTAMIC ACID; GLYCINE RECEPTOR; LAMOTRIGINE; NCS 382; NEUROTRANSMITTER; PHENOBARBITAL; PHENYTOIN; SHORT CHAIN FATTY ACID; SUCCINATE SEMIALDEHYDE DEHYDROGENASE; SUCCINIC ACID; SUCCINIC SEMIALDEHYDE; TAURINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN;

4 AMINOBUTYRIC ACID METABOLISM; ABDOMINAL PAIN; ADJUVANT THERAPY; AGITATION; ANXIETY; ATAXIA; AUTISM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CONFERENCE PAPER; CONFUSION; CONSTIPATION; COORDINATION; DEPRESSION; DEVELOPMENTAL DISORDER; DIPLOPIA; DROWSINESS; DRUG EFFICACY; DYSPRAXIA; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; ENZYME SUBSTRATE; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; INBORN ERROR OF METABOLISM; LANGUAGE DISABILITY; MENTAL DEFICIENCY; METABOLITE; MUSCLE HYPOTONIA; NEUROLOGIC DISEASE; NONHUMAN; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SPEECH DISORDER; SUCCINATE SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; TREMOR; VISUAL FIELD DEFECT;

ALDEHYDE OXIDOREDUCTASES; AMINO ACID METABOLISM, INBORN ERRORS; ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; GAMMA-AMINOBUTYRIC ACID; HUMANS; SUCCINATE-SEMIALDEHYDE DEHYDROGENASE; VIGABATRIN;

EID: 0041365747     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10626     Document Type: Conference Paper

References (35)

1. Gibson KM, Jakobs C. Disorders of beta and gamma amino acids in free and peptide linked forms. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th edit. New York: McGraw-Hill, 2002:2079-2105.
2. Gibson KM, Sweetman L, Nyhan WL, et al. Succinic semial-dehyde dehydrogenase deficiency: an inborn error of gamma-aminobutyric acid metabolism. Clin Chim Acta 1983;133:33-42.
3. Jakobs C, Bojasch M, Monch E, et al. Urinary excretion of gamma-hydroxybutyric acid in a patient with neurological abnormalities: the probability of a new inborn error of metabolism. Clin Chim Acta 1981;111:169-178.
4. Gibson KM, Sweetman L, Nyhan WL, et al. Defective succinic semialdehyde dehydrogenase activity in 4-hydroxybutyric aciduria. Eur J Pediatr 1984;142:257-259.
5. Gibson KM, Lee CF, Chambliss KL, et al. 4-Hydroxybutyric aciduria: application of a fluorometric assay to the determination of succinic semialdehyde dehydrogenase activity in extracts of cultured human lymphoblasts. Clin Chim Acta 1991;196:219-222.
6. Gibson KM, Aramaki S, Sweetman L, et al. Stable isotope dilution analysis of 4-hydroxybutyric acid: an accurate method for quantitation in physiological fluids and the prenatal diagnosis of 4-hydroxybutyric aciduria. Biomed Environ Mass Spectrom 1990;19:89-93.
7. Jakobs C, Ogier H, Rabier D, Gibson KM. Prenatal detection of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria) [Letter]. Prenat Diag 1993;13:150.
8. Gibson KM, Baumann C, Ogier H, et al. Pre-and postnatal diagnosis of succinic semialdehyde dehydrogenase deficiency using enzyme and metabolite assays. J Inherit Metab Dis 1994;17:732-737.
9. Hogema BM, Akaboshi S, Taylor M, et al. Prenatal diagnosis of succinic semialdehyde dehydrogenase deficiency: increased accuracy employing DNA, enzyme, and metabolite analyses. Mol Genet Metab 2001;72:218-222.
10. Gibson KM, Hoffman G, Nyhan WL, et al. 4-hydroxybutyric aciduria in a patient without ataxia or convulsions. Eur J Pediatr 1988;147:529-531.
11. Gibson KM, Christensen E, Jakobs C, et al. The clinical phenotype of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria): case reports of 23 new patients. Pediatrics 1997;99:567-574.
12. Gibson KM, Hoffman GF, Hodson AK, et al. 4-Hydroxybutryric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn error of GABA metabolism. Neuropediatrics 1998;29:14-22.
13. Cash CD. Gamma hydroxybutyrate: an overview of the pros and cons for it being a neurotransmitter and/or useful therapeutic agent. Neurosci Biobehav Rev 1994;18:291-304.
14. Trettel F, Malaspina P, Jodice C, et al. Human succinic semialdehyde dehydrogenase: molecular cloning and chromosomal localization. Adv Exp Med Biol 1997;414:253-260.
15. Maitre M. The γγp-hydroxybutyrate signaling system in brain: organization and functional implication. Prog Neurobiol 1997;51:337-361.
16. Snead OC. The γγp-hydroxybutyrate model of generalized absence seizures: further characterization and comparison to other absence models. Epilepsia 1988;29:361-368.
17. Snead OC. Gamma-hydroxybutyrate in the monkey. I. Electroencephalographic, behavioural and pharmacokinetic studies. Neurology 1978;28:636-642.
18. Goldschak M, Dzoljic MR, Bonta IL. Slow wave sleep and a state resembling absence epilepsy induced in rats by gamma-hydroxybutyrate. Eur J Pharmacol 1977;44:105-111.
19. Jaeken J, Casaer P, deCock P, et al. Vigabatrin in GABA metabolism disorders. Lancet 1989;1:1074.
20. Gibson KM, DeVivo DC, Jakobs C. Vigabatrin therapy in a patient with succinic semialdehyde dehydrogenase deficiency. Lancet 1989;2:1105-1106.
21. Howells DW, Jakobs C, Kok R, et al. Vigabatrin therapy in succinic semialdehyde dehydrogenase deficiency. Mol. Neuropharmacol 1992;2:181-184.
22. Jakobs C, Michael T, Jaeger E, et al. Further evaluation of Vigabatrin therapy in 4-hydroxybutyric aciduria. Eur J Pediatr 1992;151:466-468.
23. Uziel G, Bardelli P, Pantaleoni C, et al. 4-Hydroxybutyric aciduria: clinical findings and Vigabatrin therapy. J Inher Metab Dis 1993;16:520-522.
24. Dietz B, Aguigah G, Witting W, Aksu F. Vigabatrin-Therapie bei einem 7 jahrigen Jungen mit Succinat-Semialdehyd-Dehydrogenase Mangel. Monatsschr Kinderheilkd 1994;142:762.
25. Gibson KM, Jakobs C, Ogier H, et al. Vigabatrin therapy in six patients with succinic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis 1995;18:143-146.
26. Matern D, Lenhert W, Gibson KM, et al. Seizures in a boy with succinic semialdehyde dehydrogenase deficiency treated with Vigabatrin (-vinyl-GABA). J Inher Metab Dis 1996;19:313-328.
27. Gross Tsur V, Banin E, Shahar E, et al. Visual impairment in children with epilepsy treated with Vigabatrin. Ann Neurol 2000;48:60-64.
28. Malmgren K, Ben-Menachem E, Frisen L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 2001;42:609-615.
29. Spence SJ, Sankar R. Visual field deficits and other ophthalmological disturbances associated with Vigabatrin. Drug Safety 2001;24:385-414.
30. Hogema BM, Gupta M, Senephansiri H, et al. Pharmacologic rescue of lethal seizures in mice deficiency in succinate semialdehyde dehydrogenase. Nat. Genet. 2001;29:212-216.
31. Gibson KM, Schor DSM, Gupta M, et al. Focal neurometabolic alterations in mice deficient for succinate semialdehde dehydrogenase. J Neurochem 2002;81:71-79.
32. Gupta M, Greven R, Jansen EE, et al. Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). J Pharmacol Exp Ther 2002;302(1):180-187.
33. McBride WJ, Frederickson RCA. Taurine as a possible inhibitory transmitter in the cerebellum. Fed. Proc. 1980;39:2701-2705.
34. B receptor agonist. Eur J Pharmacol 1997;321:67-75.
35. B receptors. Naunyn Schmiedelbergs Arch Pharmacol 1998;357:611-619.